Deferasirox for managing transfusional iron overload in people with sickle cell disease-Reference-Cited by-同舟云学术

Deferasirox for managing transfusional iron overload in people with sickle cell disease

Published:2014-06-04 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Meerpohl Joerg J¹,Schell Lisa K²,Rücker Gerta³,Motschall Edith⁴,Fleeman Nigel⁵,Niemeyer Charlotte M⁶,Bassler Dirk⁷

Affiliation:

1. Medical Center - Univ. of Freiburg, Faculty of Medicine, Univ. of Freiburg; Cochrane Germany; Breisacher Straße 153 Freiburg Germany 79110

2. Institute for Quality and Efficiency in Health Care (IQWiG); Cologne Germany

3. Faculty of Medicine and Medical Center - University of Freiburg; Institute for Medical Biometry and Statistics; Stefan-Meier-Str. 26 Freiburg Germany 79104

4. Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg; Center for Medical Biometry and Medical Informatics; Stefan-Meier-Str. 26 Freiburg Germany 79104

5. University of Liverpool; Liverpool Reviews & Implementation Group; 2nd Floor, Sherrington Buildings Ashton Street Liverpool UK L69 3GE

6. University Medical Center Freiburg; Pediatric Hematology & Oncology, Center for Pediatrics & Adolescent Medicine; Mathildenstrasse 1 Freiburg Germany 79106

7. University Hospital Zurich and University of Zurich; Department of Neonatology; Frauenklinikstrasse 10 Zurich Switzerland

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD007477.pub3/fullpdf

Reference109 articles.

1. Cappellini MD Vichinsky E Ford JM Rabault B Porter J Evaluation of deferasirox (Exjade (R), ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) <= 1000 ng/mL in long-term studies Blood 2007 16B

2. Cappellini MD Vichinsky E Galanello R Piga A Williamson P Porter JB Long-term treatment with deferasirox (Exjade (R), ICL670), a once-daily oral iron chelator, is effective in patients with transfusion-dependent anemias Blood 2007 816A

3. Piga A Vichinsky E Forni GL Kilinc Y Maseruka H Kattamis A Long-term efficacy and safety with deferasirox (Exjade (R), ICL670), a once-daily oral iron chelator, in pediatric patients Blood 2007 815A

4. Vichinsky E Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade®, ICL670) or deferoxamine (DFO) [abstract] 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA 2006 Abstract no: 174

5. Vichinsky E Results of a randomized, controlled phase two trials of deferasirox (Exjade®, ICL670) in sickle cell disease patients with chronic overload [abstract] 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006 Abstract no: 175

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ferroptosis as an emerging target in sickle cell disease;Current Research in Toxicology;2024

2. Lactate: A Theranostic Biomarker for Metabolic Psychiatry?;Antioxidants;2023-08-22

3. Caffeic acid and ferulic acid can improve toxicological damage caused by iron overload mediated by carbonic anhydrase inhibition;Drug and Chemical Toxicology;2022-11-29

4. In silico and in vivo protective effect of Morus nigra leaves on oxidative damage induced by iron overload;Drug and Chemical Toxicology;2021-10-18

5. The Spectrum of Ocular Manifestations in Patients with Waldenström’s Macroglobulinemia;Ocular Immunology and Inflammation;2021-07-16